Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 507 participants.

Also called NCT03066830

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 507 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03066830
  • EudraCT 2016-002826-35
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Estonia, Hungary, Poland, Romania, Slovakia, South Korea, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03066830. Randomized; double masking; primary purpose treatment. Start 2017-02-24 (actual); primary completion 2019-04-17 (actual). Results posted on 2021-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sotagliflozin (SAR439954)
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin
Intervention (Drug)
Sulfonylurea
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03066830
Content hash
c07f8e42b6138b6044a2a4667998f57fcdb889d9ef76e6c0c7e7d1a856582240